Haloperidol News and Research

RSS
Haloperidol is a typical antipsychotic. It is in the butyrophenone class of antipsychotic medications and has pharmacological effects similar to the phenothiazines.
Psychotic reactions associated with natural testosterone booster products

Psychotic reactions associated with natural testosterone booster products

Multicomponent strategies needed to prevent in-hospital delirium

Multicomponent strategies needed to prevent in-hospital delirium

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Study shows effects of psychotropic drug treatment on brain morphology

Study shows effects of psychotropic drug treatment on brain morphology

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Twelve institutions receive NPCRC and American Cancer Society grants for palliative care research

Twelve institutions receive NPCRC and American Cancer Society grants for palliative care research

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Common psychiatric drugs could slow dementia

Common psychiatric drugs could slow dementia

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Tel Aviv University finds estrogen may protect women from psychosis

Tel Aviv University finds estrogen may protect women from psychosis

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial